Partner Therapeutics bets on the medicine already in the room

In February 2018, a new biotech company acquired something unusually concrete: a medicine and the factory that made it. Partner Therapeutics bought global rights to Leukine from Sanofi, along with a dedicated biologics facility in Lynnwood, Washington. The drug had first won FDA approval in 1991. For a young company, this was an interesting choice of starting equipment.

• The starting point: an established immune stimulant, manufacturing capability, and a $60 million Series A.
• The next chapter: U.S. commercialization rights to Bizengri, an antibody for specific NRG1 fusion-positive cancers.
• The useful lesson: acquiring a medicine still leaves development, supply, diagnosis and access to solve.

A different place to begin

There is an attractive story about biotechnology in which everything begins with a discovery. Someone identifies a target, invents a molecule, and waits for the world to recognize its importance. Partner Therapeutics starts its story farther down the road, where a promising or approved medicine needs an organization willing to do the remaining work.

Robert Mulroy and oncologist Debasish Roychowdhury formally launched the company in January 2018, following a 2017 start. Both had substantial industry experience. Mulroy had co-founded and led Merrimack; Roychowdhury had headed Sanofi’s global oncology division. Their stated focus was approved and late-stage therapies. This made the Leukine purchase a practical expression of the original plan.

The financing announcement supplied a useful phrase. Adams Street investor Terry Gould described the proposed business as a translational bridge. Perceptive Advisors, Adams Street Partners and MidCap Financial backed the $60 million round. The money supported pipeline development and commercial operations. The acquisition price was undisclosed, so the financing total should not be mistaken for the price of Leukine.

“a translational bridge”

Terry Gould, Adams Street Partners, on PTx’s late-stage oncology approach, 2018

The older drug with unfinished business

Leukine contains sargramostim, a form of granulocyte-macrophage colony-stimulating factor, or GM-CSF. Its established roles include supporting blood-cell recovery in specified chemotherapy and transplant settings. It stimulates a range of white blood cells. That biology helps explain why the company has investigated applications beyond its original oncology business.

In March 2018, FDA approved Leukine to increase survival after radiation exposure severe enough to suppress bone marrow. The agency used its Animal Rule, because researchers cannot ethically expose people to potentially lethal radiation to test a treatment. Cancer supportive care and radiation preparedness look like separate markets until one notices their shared problem: damaged blood-cell production.

The European extension arrived in August 2025. Imreplys, also sargramostim, received EU authorization for hematopoietic acute radiation syndrome. Approval came under exceptional circumstances, with further evidence obligations. Here, the commercial opportunity carries a particular scientific burden: preparing for an emergency whose treatment cannot be tested through an ordinary human efficacy trial.

Then came the molecular address

In December 2024, Partner Therapeutics added a different kind of medicine. Merus licensed it exclusive U.S. commercialization rights to zenocutuzumab for NRG1 fusion-positive cancer. Two days after the agreement was announced, FDA approved the antibody, branded Bizengri, for specified previously treated advanced pancreatic and non-small cell lung cancers.

Bizengri is a bispecific antibody that binds HER2 and HER3. Its clinical address is unusually precise: cancers carrying an NRG1 gene fusion. The relevant connection between patients is therefore molecular as well as anatomical. A lung tumor and a pancreatic tumor can belong in the same therapeutic conversation when that alteration is present.

In May 2026, FDA added previously treated advanced NRG1 fusion-positive cholangiocarcinoma, a bile-duct cancer. The agency’s efficacy analysis involved 19 evaluable patients and a 36.8% confirmed response rate, with a wide confidence interval. Those numbers describe a small trial population, not a promise to every patient. Infusion reactions, lung inflammation and cardiac dysfunction are among the drug’s labeled risks.

The economics are equally specific. Merus receives an upfront payment, sales milestones and royalties. Its public filings describe up to $130 million in commercialization milestones. That is a contingent ceiling, not a sum already spent. Partner Therapeutics assumes commercial responsibilities and certain development and manufacturing expenses: the agreement buys an opportunity accompanied by a substantial to-do list.

The experiment that did not oblige

Repurposing has limits, and Partner Therapeutics has published an instructive example. SCOPE randomized 600 non-hospitalized, high-risk COVID-19 patients to inhaled sargramostim or placebo. Its primary question was whether treatment prevented progression measured by emergency-room visits, hospitalization or death through day 28. The study found no difference between the arms on that endpoint.

The company also reported improvement in a secondary symptom measure and exploratory immune findings. Those observations may justify more questions; they do not erase the primary result. The distinction matters to anyone copying this business approach. Familiarity with a drug’s mechanism cannot substitute for evidence that it helps a particular population in a particular setting.

The work between a vial and a patient

Partner Therapeutics serves clinicians and healthcare institutions treating patients with cancer and other serious conditions, while its health-security work involves public-sector collaborators. A 2021 partnership with BARDA and Labcorp Drug Development sought to identify immunoparalyzed sepsis patients through monocyte HLA-DR testing and evaluate Leukine in that selected group. Again, defining the patient is part of developing the treatment.

Its position in the market is consequently broader than a licensing desk. The company combines research, manufacturing, development and commercialization. Other growth factors, including filgrastim and pegfilgrastim, offer alternatives in some supportive-care and radiation settings; the relevant comparison depends on the indication. For precision oncology, systemic therapies and clinical trials remain part of the treatment landscape.

The transferable idea is to assess the whole route to use before buying the rights. Can the medicine be supplied? Can eligible patients be identified? Can clinicians and patients navigate access? Partner Therapeutics offers educational and patient-support resources alongside its products. For a developer, it is a potential commercial partner; for a clinician, a source of product information. Discovery supplies the possibility. These less glamorous tasks determine how much of it survives contact with practice.